The COVID-19 pandemic has challenged the health care system worldwide and has spread to more than 200 countries, causing hundreds of millions confirmed cases and several million deaths (Johns Hopkins Coronavirus Resource Center, 2021).

Data from multiple studies have shown consistently that older age and comorbidities such as cardiovascular disease, diabetes mellitus (DM), hypertension, and chronic obstructive pulmonary disease (COPD) have been associated with severe illness and increased mortality (Zhou et al., 2020).

Several studies on COVID-19 mortality suggested that patients with cancer had poor outcomes (Kuderer et al., 2020; Rivera et al., 2020; He et al., 2020; Albiges et al., 2020; Robilotti et al., 2020; Lee et al., 2020; Mehta et al., 2020; Tian et al., 2020; Lunski et al., 2021; Sun et al., 2020). Many of these studies included only patients with cancer and did not have a comparator group of patients without cancer (Kuderer et al., 2020; Rivera et al., 2020; He et al., 2020; Albiges et al., 2020; Robilotti et al., 2020). Other studies compared COVID-19 mortality between patients with and without cancer and found that patients with cancer had worse outcomes (Mehta et al., 2020; Tian et al., 2020; Lunski et al., 2021; Sun et al., 2020; Rüthrich et al., 2021). However, all of these comparative studies included a relatively small number of patients with cancer and were restricted to a particular country, which limits their generalizability to patients with cancer worldwide.

Given that many of the therapeutic studies on COVID-19 were conducted in patients without cancer and given the poor outcomes of COVID-19 reported in patients with cancer (Mehta et al., 2020; Tian et al., 2020; Lunski et al., 2021; Sun et al., 2020; Rüthrich et al., 2021; Beigel et al., 2020; Salazar et al., 2021; Libster et al., 2021; Janiaud et al., 2021; Horby et al., 2021), we aimed to conduct a large multicenter study to compare the impact of these various treatments on the outcome in patients with cancer vs patients without cancer.

Therefore, given the global spread of the COVID-19 pandemic and the worldwide prevalence of cancer, we undertook this international initiative that included 16 centers from five continents to study and compare the clinical course, risk factors, and treatment modalities impact on outcomes of COVID-19 in patients with cancer vs patients without cancer on a worldwide basis.

A total of 4015patients diagnosed with COVID-19 by PCR were included in the study. After excluding 18 patients who had missing demographics and 31 patients younger than 18y, we evaluated 3966 COVID-19 patients: 2851 without cancer and 1115 with cancer (see Figure 1 for a consort flow diagram of patient attrition in analyses).

Figure 1

Download asset Open asset

Unlike the previously published studies that compared patients with COVID-19 with and without cancer, our study included a large number of patients with cancer from five different continents. Our findings demonstrate that cancer is not an independent risk factor for increased 30 day all-cause mortality in a multivariable logistic regression analyses that accounted for the treatment differences among the countries, which is inconsistent with a recent large study in the US that showed that patients recently receiving cancer treatment had a worse outcome (Chavez-MacGregor et al., 2022). The higher mortality rate observed in patients with cancer by univariable analysis seems to be driven by patients with lung cancer and patients with hematological malignancies, a finding that is consistent with prior literature (Lee et al., 2020; Mehta et al., 2020). Furthermore, lymphopenia which is observed frequently in patients with hematological malignancy was independently associated with higher COVID-19 mortality according to our country-adjusted multivariable analyses. Two large studies in COVID-19 patients with cancer have shown that lymphopenia was independently associated with increased 30 day mortality (Lunski et al., 2021; Schmidt et al., 2022). In addition, the mortality rate in the patients with solid tumors other than lung cancer was not different from the mortality rate in the patients without cancer.

Most of the other independent risk factors that we identified for 30 day mortality after a diagnosis of COVID-19 have also been commonly reported as risk factors for mortality in previous studies of COVID-19 in patients with and without cancer with older age (≥65y) being the strongest independent predictor of 30 day mortality in our study (Zhou et al., 2020; Kuderer et al., 2020; Rivera et al., 2020; He et al., 2020; Albiges et al., 2020; Robilotti et al., 2020; Lee et al., 2020; Mehta et al., 2020; Tian et al., 2020; Lunski et al., 2021; Sun et al., 2020; Rüthrich et al., 2021). In our study, the patients with cancer had a more complicated course after discharge from the hospital; specifically, they more frequently required supplemental oxygen and readmission within 30 days after COVID-19 diagnosis.

The presentation pattern of COVID-19 in patients with cancer was different to that of patients without cancer. Patients with cancer seemed to be less symptomatic. This could be related to the fact that patients with cancer tended to be older, with fewer inflammatory cells (neutrophils and lymphocytes), and more often on corticosteroids. Levels of inflammatory biomarkers were also higher in patients with cancer, particularly D-dimer, ferritin, and procalcitonin.

On multivariable analysis, the only therapeutic agent that independently decreased 30 day all-cause mortality among all patients and in patients with cancer was remdesivir, even after accounting for treatment diffrences among countries. Upon further analysis, remdesivir was found to further decrease mortality in patients with pneumonia and mild hypoxia who were receiving low-flow oxygen (≤6l/min) and not in patients with severe advanced pneumonia who were receiving high-flow oxygen and/or ventilatory support. This is consistent with a large multicenter prospective randomized placebo-controlled trial - Adaptive COVID-19 Treatment Trial-1 (ACTT-1), that found that remdesivir significantly reduced the time to recovery and 28d mortality in patients who were on low-flow oxygen at baseline but not in patients who were on mechanical ventilation or extracorporeal membrane oxygenation at baseline (Beigel et al., 2020).

In a meta-analysis that examined four large prospective randomized trials, remdesivir was shown to be associated with reduced 14 d mortality and reduced need for mechanical ventilation (Shrestha et al., 2021), which also supports our analysis.

In contrast, the WHO-sponsored multinational Solidarity Trial of COVID-19 hospitalized patients who were randomly assigned to either remdesivir (2750patients) or standard of care (2708patients) showed no difference in overall 28d mortality (Pan et al., 2021). However, in two large meta-analyses that each examined more than 13,000 COVID-19 patients from randomized and non-randomized studies, including the WHO randomized trial, remdesivir was associated with a significant improvement in the 28d recovery rate (Rezagholizadeh et al., 2021; Lai et al., 2021). Furthermore, in a large study evaluating treatments and outcomes of COVID-19 among patients with cancer, remdesivir alone was significantly associated with a lower 30 day all-cause mortality rate than other treatments (including high-dose corticosteroids and tocilizumab; Rivera et al., 2020). In addition, in a large multicenter matched controlled study involving mostly patients without cancer, Mozaffari et al. demonstrated that remdesivir was significantly effective in reducing mortality in patients on low-flow oxygen but not patients with advanced disease on high-flow oxygen and ventilator support (Mozaffari et al., 2022). More recently, a prospective randomized, double blind, placebo-controlled study (involving mainly patients without cancer) showed that early initiation of remdesivir prevents progression to severe COVID-19 (Gottlieb et al., 2022).

Therefore, the cumulative data in the literature do support our findings that remdesivir in all patients particularly in patients with cancer improves outcome and may reduce mortality especially if started early in COVID-19 patients with moderate pneumonia who are receiving low-flow oxygen who fit into the stage II of the three-stage COVID-19 classification previously proposed by Siddiqi and Mehra, 2020.

The use of corticosteroids (dexamethasone 6mg/d) was shown in a large randomized open-label study conducted in the United Kingdom to be associated with reduced 28d mortality, particularly in patients requiring oxygen supplementation and invasive ventilation who receive corticosteroids after 7d from the onset of symptoms (Horby et al., 2021). Subsequently, two meta-analyses of several prospective randomized trials demonstrated that corticosteroid use was significantly associated with a decrease in COVID-19 mortality (Sterne et al., 2020; Siemieniuk et al., 2020). In our study, we found that if corticosteroids were started more than 5d after the PCR diagnosis of COVID-19, there was a trend toward a reduction in 30 day COVID-19 mortality compared to starting corticosteroids earlier. 5 d after diagnosis by PCR testing would possibly be equivalent to 7d after the onset of symptoms since the average time from symptom onset to PCR diagnosis has been estimated to be 2–3d (Kucirka et al., 2020). Furthermore, by multivariable analysis and upon further subanalysis (Supplementary file 1), remdesivir was found to improve outcome independently of the effect of steroids.

Our study has several limitations. First, the retrospective design precluded complete assessment of disease progression in the outpatients, which limited their input into the general study. Second, some non-cancer centers contributed data only on their hospitalized patients who were likely sicker. This may have biased the data toward a higher rate of hospitalization among patients without cancer and made the data more heterogeneous. In addition, the predominance of symptomatic patients (87%) might also limit our evaluation of the impact of cancer in the whole picture of the disease. Third, our data contained a lot of missing values due to the nature of data collection. However, we performed sensitivity analyses to evaluate its impact on our primary analyses, and it showed that overall this impact was limited. Most independent predictors were identified by both complete-case and multiple imputation analyses with similar effects. The differences between the two analysis methods in identifying a few independent mortality predictors were probably due to the sample size changes from complete-case analyses to multiple imputation analyses. Last, this study was conducted prior to the introduction of COVID vaccines and included patients who were not vaccinated and who were infected by early variants which limits the generalizability of our results to contemporary COVID-19 patients. A multinational European registry showed that severity of COVID-19 and mortality in cancer patients have improved since 2020. This could be multifactorial related to earlier diagnosis, improved management including current antivirals, monoclonal antibodies, vaccination, as well as different circulating variants of the virus that could be associated with less severe disease than the earlier strains (Pinato et al., 2022). However, a recent study comparing vaccinated and unvaccinated patients with cancer showed that despite the protective role of vaccination, vulnerable patients with cancer, particularly those with risk factors such as lymphopenia, active and progressing cancer, and advanced age, can develop severe and fatal breakthrough infections (Schmidt et al., 2022).

In conclusion, this is the largest multicenter worldwide study comparing COVID-19 in patients with cancer to those without. In this study, although the limited effect size, underlying malignancy was not found to be an independent risk factor for a higher 30 day all-cause COVID-19 mortality. However, lymphopenia and anemia were frequently observed in patients with hematological malignancies, and patients with lung cancer were associated with the highest risks for poor outcome. Finally, remdesivir stood out as the only therapeutic agent independently associated with decreased 30 day mortality, particularly in patients with cancer on low-flow oxygen. Corticosteroids tended to be most useful if given more than 5d after COVID-19 diagnosis. The role of these therapeutics and their timing of administration should be verified in larger studies, especially in patients with cancer, who tend to have a higher degree of immunosuppression, which may lead to prolongation of the viral phase.

We are unable to share the data given our restriction policy and the fact that this study includes data from 16 centers and from the five continents. We do not have an agreement or the permission to share our data and other centers’ data. All the analyses were performed using SAS version 9.4 (SAS Institute Inc, Cary, NC).

1. 1. Albiges L
   2. Foulon S
   3. Bayle A
   4. Gachot B
   5. Pommeret F
   6. Willekens C
   7. Stoclin A
   8. Merad M
   9. Griscelli F
   10. Lacroix L
   11. Netzer F
   12. Hueso T
   13. Balleyguier C
   14. Ammari S
   15. Colomba E
   16. Baciarello G
   17. Perret A
   18. Hollebecque A
   19. Hadoux J
   20. Michot J-M
   21. Chaput N
   22. Saada V
   23. Hauchecorne M
   24. Micol J-B
   25. Sun R
   26. Valteau-Couanet D
   27. André F
   28. Scotte F
   29. Besse B
   30. Soria J-C
   31. Barlesi F

   (2020) Determinants of the outcomes of patients with cancer infected with SARS-cov-2: results from the Gustave Roussy cohort

   Nature Cancer 1:965–975.

   https://doi.org/10.1038/s43018-020-00120-5

   • PubMed
   • Google Scholar
2. 1. Beigel JH
   2. Tomashek KM
   3. Dodd LE
   4. Mehta AK
   5. Zingman BS
   6. Kalil AC
   7. Hohmann E
   8. Chu HY
   9. Luetkemeyer A
   10. Kline S
   11. Lopez de Castilla D
   12. Finberg RW
   13. Dierberg K
   14. Tapson V
   15. Hsieh L
   16. Patterson TF
   17. Paredes R
   18. Sweeney DA
   19. Short WR
   20. Touloumi G
   21. Lye DC
   22. Ohmagari N
   23. Oh M-D
   24. Ruiz-Palacios GM
   25. Benfield T
   26. Fätkenheuer G
   27. Kortepeter MG
   28. Atmar RL
   29. Creech CB
   30. Lundgren J
   31. Babiker AG
   32. Pett S
   33. Neaton JD
   34. Burgess TH
   35. Bonnett T
   36. Green M
   37. Makowski M
   38. Osinusi A
   39. Nayak S
   40. Lane HC
   41. ACTT-1 Study Group Members

   (2020) Remdesivir for the treatment of Covid-19-final report

   The New England Journal of Medicine 383:1813–1826.

   https://doi.org/10.1056/NEJMoa2007764

   • PubMed
   • Google Scholar
3. 1. Chavez-MacGregor M
   2. Lei X
   3. Zhao H
   4. Scheet P
   5. Giordano SH

   (2022) Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer

   JAMA Oncology 8:69–78.

   https://doi.org/10.1001/jamaoncol.2021.5148

   • PubMed
   • Google Scholar
4. 1. Gottlieb RL
   2. Vaca CE
   3. Paredes R
   4. Mera J
   5. Webb BJ
   6. Perez G
   7. Oguchi G
   8. Ryan P
   9. Nielsen BU
   10. Brown M
   11. Hidalgo A
   12. Sachdeva Y
   13. Mittal S
   14. Osiyemi O
   15. Skarbinski J
   16. Juneja K
   17. Hyland RH
   18. Osinusi A
   19. Chen S
   20. Camus G
   21. Abdelghany M
   22. Davies S
   23. Behenna-Renton N
   24. Duff F
   25. Marty FM
   26. Katz MJ
   27. Ginde AA
   28. Brown SM
   29. Schiffer JT
   30. Hill JA

   (2022) Early remdesivir to prevent progression to severe Covid-19 in outpatients

   New England Journal of Medicine 386:305–315.

   https://doi.org/10.1056/NEJMoa2116846

   • PubMed
   • Google Scholar
5. 1. He W
   2. Chen L
   3. Chen L
   4. Yuan G
   5. Fang Y
   6. Chen W
   7. Wu D
   8. Liang B
   9. Lu X
   10. Ma Y
   11. Li L
   12. Wang H
   13. Chen Z
   14. Li Q
   15. Gale RP

   (2020) COVID-19 in persons with haematological cancers

   Leukemia 34:1637–1645.

   https://doi.org/10.1038/s41375-020-0836-7

   • PubMed
   • Google Scholar
6. 1. Horby P
   2. Lim WS
   3. Emberson JR
   4. Mafham M
   5. Bell JL
   6. Linsell L
   7. Staplin N
   8. Brightling C
   9. Ustianowski A
   10. Elmahi E
   11. Prudon B
   12. Green C
   13. Felton T
   14. Chadwick D
   15. Rege K
   16. Fegan C
   17. Chappell LC
   18. Faust SN
   19. Jaki T
   20. Jeffery K
   21. Montgomery A
   22. Rowan K
   23. Juszczak E
   24. Baillie JK
   25. Haynes R
   26. Landray MJ
   27. RECOVERY Collaborative Group

   (2021) Dexamethasone in hospitalized patients with covid-19

   The New England Journal of Medicine 384:693–704.

   https://doi.org/10.1056/NEJMoa2021436

   • PubMed
   • Google Scholar
7. 1. Janiaud P
   2. Axfors C
   3. Schmitt AM
   4. Gloy V
   5. Ebrahimi F
   6. Hepprich M
   7. Smith ER
   8. Haber NA
   9. Khanna N
   10. Moher D
   11. Goodman SN
   12. Ioannidis JPA
   13. Hemkens LG

   (2021) Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis

   JAMA 325:1185–1195.

   https://doi.org/10.1001/jama.2021.2747

   • PubMed
   • Google Scholar
8. Website

   1. Johns Hopkins Coronavirus Resource Center

   (2021) COVID-19 Map

   Accessed April 29, 2021.

   https://coronavirus.jhu.edu/map.html
9. 1. Kucirka LM
   2. Lauer SA
   3. Laeyendecker O
   4. Boon D
   5. Lessler J

   (2020) Variation in false-negative rate of reverse transcriptase polymerase chain reaction–based SARS-cov-2 tests by time since exposure

   Annals of Internal Medicine 173:262–267.

   https://doi.org/10.7326/M20-1495

   • PubMed
   • Google Scholar
10. 1. Kuderer NM
    2. Choueiri TK
    3. Shah DP
    4. Shyr Y
    5. Rubinstein SM
    6. Rivera DR
    7. Shete S
    8. Hsu CY
    9. Desai A
    10. de Lima Lopes G
    11. Grivas P
    12. Painter CA
    13. Peters S
    14. Thompson MA
    15. Bakouny Z
    16. Batist G
    17. Bekaii-Saab T
    18. Bilen MA
    19. Bouganim N
    20. Larroya MB
    21. Castellano D
    22. Del Prete SA
    23. Doroshow DB
    24. Egan PC
    25. Elkrief A
    26. Farmakiotis D
    27. Flora D
    28. Galsky MD
    29. Glover MJ
    30. Griffiths EA
    31. Gulati AP
    32. Gupta S
    33. Hafez N
    34. Halfdanarson TR
    35. Hawley JE
    36. Hsu E
    37. Kasi A
    38. Khaki AR
    39. Lemmon CA
    40. Lewis C
    41. Logan B
    42. Masters T
    43. McKay RR
    44. Mesa RA
    45. Morgans AK
    46. Mulcahy MF
    47. Panagiotou OA
    48. Peddi P
    49. Pennell NA
    50. Reynolds K
    51. Rosen LR
    52. Rosovsky R
    53. Salazar M
    54. Schmidt A
    55. Shah SA
    56. Shaya JA
    57. Steinharter J
    58. Stockerl-Goldstein KE
    59. Subbiah S
    60. Vinh DC
    61. Wehbe FH
    62. Weissmann LB
    63. Wu JTY
    64. Wulff-Burchfield E
    65. Xie Z
    66. Yeh A
    67. Yu PP
    68. Zhou AY
    69. Zubiri L
    70. Mishra S
    71. Lyman GH
    72. Rini BI
    73. Warner JL
    74. COVID-19 and Cancer Consortium

    (2020) Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

    Lancet 395:1907–1918.

    https://doi.org/10.1016/S0140-6736(20)31187-9

    • PubMed
    • Google Scholar
11. 1. Lai CC
    2. Chen CH
    3. Wang CY
    4. Chen KH
    5. Wang YH
    6. Hsueh PR

    (2021) Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials

    The Journal of Antimicrobial Chemotherapy 76:1962–1968.

    https://doi.org/10.1093/jac/dkab093

    • PubMed
    • Google Scholar
12. 1. Lee LY
    2. Cazier JB
    3. Angelis V
    4. Arnold R
    5. Bisht V
    6. Campton NA
    7. Chackathayil J
    8. Cheng VW
    9. Curley HM
    10. Fittall MW
    11. Freeman-Mills L
    12. Gennatas S
    13. Goel A
    14. Hartley S
    15. Hughes DJ
    16. Kerr D
    17. Lee AJ
    18. Lee RJ
    19. McGrath SE
    20. Middleton CP
    21. Murugaesu N
    22. Newsom-Davis T
    23. Okines AF
    24. Olsson-Brown AC
    25. Palles C
    26. Pan Y
    27. Pettengell R
    28. Powles T
    29. Protheroe EA
    30. Purshouse K
    31. Sharma-Oates A
    32. Sivakumar S
    33. Smith AJ
    34. Starkey T
    35. Turnbull CD
    36. Várnai C
    37. Yousaf N
    38. Kerr R
    39. Middleton G
    40. UK Coronavirus Monitoring Project Team

    (2020) COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

    Lancet 395:1919–1926.

    https://doi.org/10.1016/S0140-6736(20)31173-9

    • PubMed
    • Google Scholar
13. 1. Libster R
    2. Pérez Marc G
    3. Wappner D
    4. Coviello S
    5. Bianchi A
    6. Braem V
    7. Esteban I
    8. Caballero MT
    9. Wood C
    10. Berrueta M
    11. Rondan A
    12. Lescano G
    13. Cruz P
    14. Ritou Y
    15. Fernández Viña V
    16. Álvarez Paggi D
    17. Esperante S
    18. Ferreti A
    19. Ofman G
    20. Ciganda Á
    21. Rodriguez R
    22. Lantos J
    23. Valentini R
    24. Itcovici N
    25. Hintze A
    26. Oyarvide ML
    27. Etchegaray C
    28. Neira A
    29. Name I
    30. Alfonso J
    31. López Castelo R
    32. Caruso G
    33. Rapelius S
    34. Alvez F
    35. Etchenique F
    36. Dimase F
    37. Alvarez D
    38. Aranda SS
    39. Sánchez Yanotti C
    40. De Luca J
    41. Jares Baglivo S
    42. Laudanno S
    43. Nowogrodzki F
    44. Larrea R
    45. Silveyra M
    46. Leberzstein G
    47. Debonis A
    48. Molinos J
    49. González M
    50. Perez E
    51. Kreplak N
    52. Pastor Argüello S
    53. Gibbons L
    54. Althabe F
    55. Bergel E
    56. Polack FP
    57. Fundación INFANT–COVID-19 Group

    (2021) Early high-titer plasma therapy to prevent severe covid-19 in older adults

    The New England Journal of Medicine 384:610–618.

    https://doi.org/10.1056/NEJMoa2033700

    • PubMed
    • Google Scholar
14. 1. Lunski MJ
    2. Burton J
    3. Tawagi K
    4. Maslov D
    5. Simenson V
    6. Barr D
    7. Yuan H
    8. Johnson D
    9. Matrana M
    10. Cole J
    11. Larned Z
    12. Moore B

    (2021) Multivariate mortality analyses in COVID-19: comparing patients with cancer and patients without cancer in Louisiana

    Cancer 127:266–274.

    https://doi.org/10.1002/cncr.33243

    • PubMed
    • Google Scholar
15. 1. Mehta V
    2. Goel S
    3. Kabarriti R
    4. Cole D
    5. Goldfinger M
    6. Acuna-Villaorduna A
    7. Pradhan K
    8. Thota R
    9. Reissman S
    10. Sparano JA
    11. Gartrell BA
    12. Smith RV
    13. Ohri N
    14. Garg M
    15. Racine AD
    16. Kalnicki S
    17. Perez-Soler R
    18. Halmos B
    19. Verma A

    (2020) Case fatality rate of cancer patients with COVID-19 in a new York hospital system

    Cancer Discovery 10:935–941.

    https://doi.org/10.1158/2159-8290.CD-20-0516

    • PubMed
    • Google Scholar
16. 1. Mozaffari E
    2. Chandak A
    3. Zhang Z
    4. Liang S
    5. Thrun M
    6. Gottlieb RL
    7. Kuritzkes DR
    8. Sax PE
    9. Wohl DA
    10. Casciano R
    11. Hodgkins P
    12. Haubrich R

    (2022) Remdesivir treatment in hospitalized patients with coronavirus disease 2019 (COVID-19): a comparative analysis of in-hospital all-cause mortality in a large multicenter observational cohort

    Clinical Infectious Diseases 75:e450–e458.

    https://doi.org/10.1093/cid/ciab875

    • PubMed
    • Google Scholar
17. 1. Pan H
    2. Peto R
    3. Henao-Restrepo AM
    4. Preziosi MP
    5. Sathiyamoorthy V
    6. Abdool Karim Q
    7. Alejandria MM
    8. Hernández García C
    9. Kieny MP
    10. Malekzadeh R
    11. Murthy S
    12. Reddy KS
    13. Roses Periago M
    14. Abi Hanna P
    15. Ader F
    16. Al-Bader AM
    17. Alhasawi A
    18. Allum E
    19. Alotaibi A
    20. Alvarez-Moreno CA
    21. Appadoo S
    22. Asiri A
    23. Aukrust P
    24. Barratt-Due A
    25. Bellani S
    26. Branca M
    27. Cappel-Porter HBC
    28. Cerrato N
    29. Chow TS
    30. Como N
    31. Eustace J
    32. García PJ
    33. Godbole S
    34. Gotuzzo E
    35. Griskevicius L
    36. Hamra R
    37. Hassan M
    38. Hassany M
    39. Hutton D
    40. Irmansyah I
    41. Jancoriene L
    42. Kirwan J
    43. Kumar S
    44. Lennon P
    45. Lopardo G
    46. Lydon P
    47. Magrini N
    48. Maguire T
    49. Manevska S
    50. Manuel O
    51. McGinty S
    52. Medina MT
    53. Mesa Rubio ML
    54. Miranda-Montoya MC
    55. Nel J
    56. Nunes EP
    57. Perola M
    58. Portolés A
    59. Rasmin MR
    60. Raza A
    61. Rees H
    62. Reges PPS
    63. Rogers CA
    64. Salami K
    65. Salvadori MI
    66. Sinani N
    67. Sterne JAC
    68. Stevanovikj M
    69. Tacconelli E
    70. Tikkinen KAO
    71. Trelle S
    72. Zaid H
    73. Røttingen JA
    74. Swaminathan S
    75. WHO Solidarity Trial Consortium

    (2021) Repurposed antiviral drugs for covid-19-interim who solidarity trial results

    The New England Journal of Medicine 384:497–511.

    https://doi.org/10.1056/NEJMoa2023184

    • PubMed
    • Google Scholar
18. 1. Pinato DJ
    2. Patel M
    3. Scotti L
    4. Colomba E
    5. Dolly S
    6. Loizidou A
    7. Chester J
    8. Mukherjee U
    9. Zambelli A
    10. Dalla Pria A
    11. Aguilar-Company J
    12. Bower M
    13. Salazar R
    14. Bertuzzi A
    15. Brunet J
    16. Lambertini M
    17. Tagliamento M
    18. Pous A
    19. Sita-Lumsden A
    20. Srikandarajah K
    21. Colomba J
    22. Pommeret F
    23. Seguí E
    24. Generali D
    25. Grisanti S
    26. Pedrazzoli P
    27. Rizzo G
    28. Libertini M
    29. Moss C
    30. Evans JS
    31. Russell B
    32. Harbeck N
    33. Vincenzi B
    34. Biello F
    35. Bertulli R
    36. Ottaviani D
    37. Liñan R
    38. Rossi S
    39. Carmona-García MC
    40. Tondini C
    41. Fox L
    42. Baggi A
    43. Fotia V
    44. Parisi A
    45. Porzio G
    46. Queirolo P
    47. Cruz CA
    48. Saoudi-Gonzalez N
    49. Felip E
    50. Roqué Lloveras A
    51. Newsom-Davis T
    52. Sharkey R
    53. Roldán E
    54. Reyes R
    55. Zoratto F
    56. Earnshaw I
    57. Ferrante D
    58. Marco-Hernández J
    59. Ruiz-Camps I
    60. Gaidano G
    61. Patriarca A
    62. Bruna R
    63. Sureda A
    64. Martinez-Vila C
    65. Sanchez de Torre A
    66. Berardi R
    67. Giusti R
    68. Mazzoni F
    69. Guida A
    70. Rimassa L
    71. Chiudinelli L
    72. Franchi M
    73. Krengli M
    74. Santoro A
    75. Prat A
    76. Tabernero J
    77. Van Hemelrijck M
    78. Diamantis N
    79. Gennari A
    80. Cortellini A
    81. OnCovid Study Group

    (2022) Time-dependent COVID-19 mortality in patients with cancer: an updated analysis of the oncovid registry

    JAMA Oncology 8:114–122.

    https://doi.org/10.1001/jamaoncol.2021.6199

    • PubMed
    • Google Scholar
19. 1. Rezagholizadeh A
    2. Khiali S
    3. Sarbakhsh P
    4. Entezari-Maleki T

    (2021) Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis

    European Journal of Pharmacology 897:173926.

    https://doi.org/10.1016/j.ejphar.2021.173926

    • PubMed
    • Google Scholar
20. 1. Rivera DR
    2. Peters S
    3. Panagiotou OA
    4. Shah DP
    5. Kuderer NM
    6. Hsu C-Y
    7. Rubinstein SM
    8. Lee BJ
    9. Choueiri TK
    10. de Lima Lopes G Jr
    11. Grivas P
    12. Painter CA
    13. Rini BI
    14. Thompson MA
    15. Arcobello J
    16. Bakouny Z
    17. Doroshow DB
    18. Egan PC
    19. Farmakiotis D
    20. Fecher LA
    21. Friese CR
    22. Galsky MD
    23. Goel S
    24. Gupta S
    25. Halfdanarson TR
    26. Halmos B
    27. Hawley JE
    28. Khaki AR
    29. Lemmon CA
    30. Mishra S
    31. Olszewski AJ
    32. Pennell NA
    33. Puc MM
    34. Revankar SG
    35. Schapira L
    36. Schmidt A
    37. Schwartz GK
    38. Shah SA
    39. Wu JT
    40. Xie Z
    41. Yeh AC
    42. Zhu H
    43. Shyr Y
    44. Lyman GH
    45. Warner JL
    46. COVID-19 and Cancer Consortium

    (2020) Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and cancer Consortium (CCC19) cohort study

    Cancer Discovery 10:1514–1527.

    https://doi.org/10.1158/2159-8290.CD-20-0941

    • PubMed
    • Google Scholar
21. 1. Robilotti EV
    2. Babady NE
    3. Mead PA
    4. Rolling T
    5. Perez-Johnston R
    6. Bernardes M
    7. Bogler Y
    8. Caldararo M
    9. Figueroa CJ
    10. Glickman MS
    11. Joanow A
    12. Kaltsas A
    13. Lee YJ
    14. Lucca A
    15. Mariano A
    16. Morjaria S
    17. Nawar T
    18. Papanicolaou GA
    19. Predmore J
    20. Redelman-Sidi G
    21. Schmidt E
    22. Seo SK
    23. Sepkowitz K
    24. Shah MK
    25. Wolchok JD
    26. Hohl TM
    27. Taur Y
    28. Kamboj M

    (2020) Determinants of COVID-19 disease severity in patients with cancer

    Nature Medicine 26:1218–1223.

    https://doi.org/10.1038/s41591-020-0979-0

    • PubMed
    • Google Scholar
22. 1. Rüthrich MM
    2. Giessen-Jung C
    3. Borgmann S
    4. Classen AY
    5. Dolff S
    6. Grüner B
    7. Hanses F
    8. Isberner N
    9. Köhler P
    10. Lanznaster J
    11. Merle U
    12. Nadalin S
    13. Piepel C
    14. Schneider J
    15. Schons M
    16. Strauss R
    17. Tometten L
    18. Vehreschild JJ
    19. von Lilienfeld-Toal M
    20. Beutel G
    21. Wille K
    22. LEOSS Study Group

    (2021) COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry

    Annals of Hematology 100:383–393.

    https://doi.org/10.1007/s00277-020-04328-4

    • PubMed
    • Google Scholar
23. 1. Salazar E
    2. Christensen PA
    3. Graviss EA
    4. Nguyen DT
    5. Castillo B
    6. Chen J
    7. Lopez BV
    8. Eagar TN
    9. Yi X
    10. Zhao P
    11. Rogers J
    12. Shehabeldin A
    13. Joseph D
    14. Masud F
    15. Leveque C
    16. Olsen RJ
    17. Bernard DW
    18. Gollihar J
    19. Musser JM

    (2021) Significantly decreased mortality in a large cohort of coronavirus disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti-severe acute respiratory syndrome coronavirus 2 (SARS-cov-2) spike protein IgG

    The American Journal of Pathology 191:90–107.

    https://doi.org/10.1016/j.ajpath.2020.10.008

    • PubMed
    • Google Scholar
24. 1. Schmidt AL
    2. Labaki C
    3. Hsu C-Y
    4. Bakouny Z
    5. Balanchivadze N
    6. Berg SA
    7. Blau S
    8. Daher A
    9. El Zarif T
    10. Friese CR
    11. Griffiths EA
    12. Hawley JE
    13. Hayes-Lattin B
    14. Karivedu V
    15. Latif T
    16. Mavromatis BH
    17. McKay RR
    18. Nagaraj G
    19. Nguyen RH
    20. Panagiotou OA
    21. Portuguese AJ
    22. Puc M
    23. Santos Dutra M
    24. Schroeder BA
    25. Thakkar A
    26. Wulff-Burchfield EM
    27. Mishra S
    28. Farmakiotis D
    29. Shyr Y
    30. Warner JL
    31. Choueiri TK
    32. COVID-19 and Cancer Consortium

    (2022) COVID-19 vaccination and breakthrough infections in patients with cancer

    Annals of Oncology 33:340–346.

    https://doi.org/10.1016/j.annonc.2021.12.006

    • PubMed
    • Google Scholar
25. 1. Shrestha DB
    2. Budhathoki P
    3. Syed NIH
    4. Rawal E
    5. Raut S
    6. Khadka S

    (2021) Remdesivir: A potential game-changer or just A myth? A systematic review and meta-analysis

    Life Sciences 264:118663.

    https://doi.org/10.1016/j.lfs.2020.118663

    • PubMed
    • Google Scholar
26. 1. Siddiqi HK
    2. Mehra MR

    (2020) COVID-19 illness in native and immunosuppressed states: a clinical–therapeutic staging proposal

    The Journal of Heart and Lung Transplantation 39:405–407.

    https://doi.org/10.1016/j.healun.2020.03.012

    • PubMed
    • Google Scholar
27. 1. Siemieniuk RA
    2. Bartoszko JJ
    3. Zeraatkar D
    4. Kum E
    5. Qasim A
    6. Díaz Martinez JP
    7. Izcovich A
    8. Rochwerg B
    9. Lamontagne F
    10. Han MA
    11. Agarwal A
    12. Agoritsas T
    13. Azab M
    14. Bravo G
    15. Chu DK
    16. Couban R
    17. Cusano E
    18. Devji T
    19. Escamilla Z
    20. Foroutan F
    21. Gao Y
    22. Ge L
    23. Ghadimi M
    24. Heels-Ansdell D
    25. Honarmand K
    26. Hou L
    27. Ibrahim S
    28. Khamis A
    29. Lam B
    30. Mansilla C
    31. Loeb M
    32. Miroshnychenko A
    33. Marcucci M
    34. McLeod SL
    35. Motaghi S
    36. Murthy S
    37. Mustafa RA
    38. Pardo-Hernandez H
    39. Rada G
    40. Rizwan Y
    41. Saadat P
    42. Switzer C
    43. Thabane L
    44. Tomlinson G
    45. Vandvik PO
    46. Vernooij RW
    47. Viteri-García A
    48. Wang Y
    49. Yao L
    50. Zhao Y
    51. Guyatt GH
    52. Brignardello-Petersen R

    (2020) Drug treatments for covid-19: living systematic review and network meta-analysis

    BMJ 370:m2980.

    https://doi.org/10.1136/bmj.m2980

    • PubMed
    • Google Scholar
28. 1. Sterne JAC
    2. Murthy S
    3. Diaz JV
    4. Slutsky AS
    5. Villar J
    6. Angus DC
    7. Annane D
    8. Azevedo LCP
    9. Berwanger O
    10. Cavalcanti AB
    11. Dequin PF
    12. Du B
    13. Emberson J
    14. Fisher D
    15. Giraudeau B
    16. Gordon AC
    17. Granholm A
    18. Green C
    19. Haynes R
    20. Heming N
    21. Higgins JPT
    22. Horby P
    23. Jüni P
    24. Landray MJ
    25. Le Gouge A
    26. Leclerc M
    27. Lim WS
    28. Machado FR
    29. McArthur C
    30. Meziani F
    31. Møller MH
    32. Perner A
    33. Petersen MW
    34. Savovic J
    35. Tomazini B
    36. Veiga VC
    37. Webb S
    38. Marshall JC
    39. WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group

    (2020) Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis

    JAMA 324:1330–1341.

    https://doi.org/10.1001/jama.2020.17023

    • PubMed
    • Google Scholar
29. Preprint

    1. Sun L
    2. Surya S
    3. Le AN
    4. Desai H
    5. Doucette A
    6. Gabriel P
    7. Ritchie M
    8. Rader D
    9. Maillard I
    10. Bange E
    11. Huang A
    12. Vonderheide RH
    13. DeMichele A
    14. Verma A
    15. Mamtani R
    16. Maxwell KN

    (2020) Rates of COVID-19-Related Outcomes in Cancer Compared to Non-Cancer Patients

    medRxiv.

    https://doi.org/10.1101/2020.08.14.20174961

    • Google Scholar
30. 1. Tian J
    2. Yuan X
    3. Xiao J
    4. Zhong Q
    5. Yang C
    6. Liu B
    7. Cai Y
    8. Lu Z
    9. Wang J
    10. Wang Y
    11. Liu S
    12. Cheng B
    13. Wang J
    14. Zhang M
    15. Wang L
    16. Niu S
    17. Yao Z
    18. Deng X
    19. Zhou F
    20. Wei W
    21. Li Q
    22. Chen X
    23. Chen W
    24. Yang Q
    25. Wu S
    26. Fan J
    27. Shu B
    28. Hu Z
    29. Wang S
    30. Yang X-P
    31. Liu W
    32. Miao X
    33. Wang Z

    (2020) Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study

    The Lancet. Oncology 21:893–903.

    https://doi.org/10.1016/S1470-2045(20)30309-0

    • PubMed
    • Google Scholar
31. 1. Zhou F
    2. Yu T
    3. Du R
    4. Fan G
    5. Liu Y
    6. Liu Z
    7. Xiang J
    8. Wang Y
    9. Song B
    10. Gu X
    11. Guan L
    12. Wei Y
    13. Li H
    14. Wu X
    15. Xu J
    16. Tu S
    17. Zhang Y
    18. Chen H
    19. Cao B

    (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in wuhan, china: a retrospective cohort study

    Lancet 395:1054–1062.

    https://doi.org/10.1016/S0140-6736(20)30566-3

    • PubMed
    • Google Scholar

Author details

1. Issam I Raad

   Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

   Contribution

   Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing

   Contributed equally with

   Ray Hachem and Anne-Marie Chaftari

   Competing interests

   No competing interests declared

2. Ray Hachem

   Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

   Contribution

   Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing

   Contributed equally with

   Issam I Raad and Anne-Marie Chaftari

   Competing interests

   No competing interests declared

3. Nigo Masayuki

   Division of Infectious Diseases, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, United States

   Contribution

   Conceptualization, Resources, Data curation, Software, Supervision, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing

   Competing interests

   No competing interests declared

4. Tarcila Datoguia

   Médica Hematologista Hospital Israelita Albert Einstein, São Paulo, Brazil

   Contribution

   Conceptualization, Resources, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Project administration, Writing – review and editing

   Competing interests

   No competing interests declared

5. Hiba Dagher

   Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

   Contribution

   Conceptualization, Resources, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Project administration, Writing – review and editing

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-8483-6977

6. Ying Jiang

   Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

   Contribution

   Conceptualization, Resources, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Project administration, Writing – review and editing

   Competing interests

   No competing interests declared

7. Vivek Subbiah

   1. MD Anderson Cancer Network, UT MD Anderson Cancer Center, Houston, United States
   2. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, United States

   Contribution

   Conceptualization, Data curation, Formal analysis, Supervision, Validation, Visualization, Writing – review and editing

   Competing interests

   No competing interests declared

8. Bilal Siddiqui

   Department of Hematology Oncology, Community Health Network, Indianapolis, United States

   Contribution

   Conceptualization, Supervision, Validation, Visualization, Writing – review and editing

   Competing interests

   No competing interests declared

9. Arnaud Bayle

   Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France

   Contribution

   Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization, Writing – review and editing

   Competing interests

   No competing interests declared

10. Robert Somer

    Cooper Medical School of Rowan University, Cooper University Health Care, Camden, United States

    Contribution

    Conceptualization, Resources, Data curation, Validation, Investigation, Visualization, Methodology, Writing – review and editing

    Competing interests

    No competing interests declared

11. Ana Fernández Cruz

    Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario Puerta de Hierro, Madrid, Spain

    Contribution

    Conceptualization, Resources, Data curation, Supervision, Investigation, Methodology, Writing – original draft, Writing – review and editing

    Competing interests

    No competing interests declared

12. Edward Gorak

    Department of Hematology Oncology, Baptist Health, Jacksonville, United States

    Contribution

    Conceptualization, Resources, Data curation, Supervision, Investigation, Methodology, Writing – original draft, Writing – review and editing

    Competing interests

    No competing interests declared

13. Arvinder Bhinder

    Department of Hematology/Oncology, Ohio Health Marion, Marion, United States

    Contribution

    Conceptualization, Resources, Data curation, Software, Supervision, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing

    Competing interests

    No competing interests declared

14. Nobuyoshi Mori

    Department of Infectious Diseases, St. Luke's International Hospital, Tokyo, Japan

    Contribution

    Conceptualization, Resources, Data curation, Software, Supervision, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0001-8815-5135

15. Nelson Hamerschlak

    Médica Hematologista Hospital Israelita Albert Einstein, São Paulo, Brazil

    Contribution

    Conceptualization, Resources, Data curation, Software, Supervision, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

16. Samuel Shelanski

    Banner MD Anderson Cancer Center – North Colorado, Greely, United States

    Contribution

    Conceptualization, Resources, Data curation, Software, Supervision, Validation, Investigation, Visualization, Writing – original draft, Writing – review and editing

    Competing interests

    No competing interests declared

17. Tomislav Dragovich

    Division of Cancer Medicine, Banner MD Anderson Cancer Center, Gilbert, United States

    Contribution

    Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization, Writing – original draft, Writing – review and editing

    Competing interests

    No competing interests declared

18. Yee Elise Vong Kiat

    Department of Medical Oncology, Tan Tock Seng Hospital, Singapore, Singapore

    Contribution

    Conceptualization, Resources, Data curation, Validation, Investigation, Visualization, Writing – original draft, Writing – review and editing

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0002-8870-1391

19. Suha Fakhreddine

    Department of Infectious Diseases, Rafik Hariri University Hospital, Beirut, Lebanon

    Contribution

    Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization, Writing – original draft, Writing – review and editing

    Competing interests

    No competing interests declared

20. Abi Hanna Pierre

    Department of Infectious Diseases, Rafik Hariri University Hospital, Beirut, Lebanon

    Contribution

    Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

21. Roy F Chemaly

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

22. Victor Mulanovich

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

23. Javier Adachi

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

24. Jovan Borjan

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Conceptualization, Resources, Data curation, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

25. Fareed Khawaja

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Conceptualization, Resources, Data curation, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

26. Bruno Granwehr

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Conceptualization, Resources, Data curation, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

27. Teny John

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

28. Eduardo Yepez Yepez

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

29. Harrys A Torres

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Resources, Data curation, Supervision, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

30. Natraj Reddy Ammakkanavar

    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Resources, Data curation, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

31. Marcel Yibirin

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Conceptualization, Resources, Data curation, Validation, Investigation

    Competing interests

    No competing interests declared

32. Cielito C Reyes-Gibby

    Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Conceptualization, Resources, Data curation, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0003-4500-6476

33. Mala Pande

    Department of Gastroenterology, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Resources, Data curation, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

34. Noman Ali

    Department of Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Resources, Data curation, Investigation, Visualization

    Competing interests

    No competing interests declared

35. Raniv Dawey Rojo

    Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Data curation, Investigation, Visualization

    Competing interests

    No competing interests declared

36. Shahnoor M Ali

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Data curation, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

37. Rita E Deeba

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Resources, Data curation, Supervision, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

38. Patrick Chaftari

    Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Resources, Data curation, Supervision, Investigation, Visualization

    Competing interests

    No competing interests declared

39. Takahiro Matsuo

    Department of Infectious Diseases, St. Luke's International Hospital, Tokyo, Japan

    Contribution

    Resources, Data curation, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

40. Kazuhiro Ishikawa

    Department of Infectious Diseases, St. Luke's International Hospital, Tokyo, Japan

    Contribution

    Resources, Data curation, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

41. Ryo Hasegawa

    Department of Infectious Diseases, St. Luke's International Hospital, Tokyo, Japan

    Contribution

    Resources, Data curation, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

42. Ramón Aguado-Noya

    Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain

    Contribution

    Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

43. Alvaro Garcia García

    Hematology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain

    Contribution

    Conceptualization, Resources, Data curation, Software, Supervision, Validation, Investigation, Visualization, Methodology

    Competing interests

    No competing interests declared

44. Cristina Traseira Puchol

    Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain

    Contribution

    Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization

    Competing interests

    No competing interests declared

45. Dong Gun Lee

    Division of Infectious Diseases, Department of Internal Medicine, Vaccine Bio Research Institute, The Catholic University of Korea, Seoul, Republic of Korea

    Contribution

    Conceptualization, Resources, Data curation, Software, Supervision, Validation, Investigation, Visualization, Methodology

    Competing interests

    No competing interests declared

46. Monica Slavin

    Department of Infectious Diseases and National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia

    Contribution

    Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization, Methodology

    Competing interests

    No competing interests declared

47. Benjamin Teh

    Department of Infectious Diseases and National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia

    Contribution

    Conceptualization, Resources, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology

    Competing interests

    No competing interests declared

48. Cesar A Arias

    Division of Infectious Diseases, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, United States

    Contribution

    Conceptualization

    Competing interests

    No competing interests declared

49. Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team

    Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team at The University of Texas MD Anderson Cancer Center, Houston, United States

    Competing interests

    No competing interests declared

50. Dimitrios P Kontoyiannis

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Resources, Data curation, Investigation

    Competing interests

    No competing interests declared

51. Alexandre E Malek

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Conceptualization, Resources, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Project administration, Writing – review and editing

    Competing interests

    No competing interests declared

52. Anne-Marie Chaftari

    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States

    Contribution

    Conceptualization, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing

    Contributed equally with

    Issam I Raad and Ray Hachem

    For correspondence

    achaftari@mdanderson.org

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0001-8097-8452

• 735

  views

• 137

  downloads

• 3

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.